Trial Report Solriamfetol improves daily fatigue symptoms in adults with [ME/CFS] after 8 weeks of treatment, 2025, Young et al

[poetinsf]

At Week 8 (p = 0.039), but not Week 6 (p = 0.270), solriamfetol improved FSI severity compared to placebo.

Anything with norepinephrine and dopamine catches my attention. But the result barely clearing the threshold at the last minute in such a small sample size is not too credible. I sure would like to see larger trial for longer with something more objective than FSI (either step count or time spent lying down). If the measure continues to improve in week 9, 10, 11 and so on, we may be onto something. We'll also need to know if the fatigue reverts to the baseline when the treatment stops.

 

[perchance dreamer]

I take Solriamfetol (brand name Sunosi in U.S.). It's comes in 75 MG and 150 MG. I split the lower dosage, so take 37.5 MG.

I don't find it energizing, but it acts as a subtle mood lift. For some reason, I also find it calming, but given how it works, I don't know why that is.

 

[Mij]

Jarod Younger youtube video about Solriamfetol here

 

[dratalanta]

For me, stimulants are helpful in the way that a bank loan is helpful. Sometimes you need the resources to do something time sensitive. But it all has to be paid back eventually.

As other posters have said, this result is meaningless without long term follow up using objective activity measures. Otherwise patients could just be borrowing again to pay off yesterday’s loan, with the total owed mounting all the time. Eventually the bailiffs will come knocking.